Redeye provides an update following Neola Medical’s Q3 2026 report. Overall, the report contained no major surprises, and the company continues to work quietly on preclinical validation of lung collapse detection and preparations for the larger US clinical study, which we expect to start in mid-2027e. In this update, we make fine-tuning adjustments to our cost estimates. We have also raised our WACC due to a higher risk-free rate, which slightly lowers our Base Case. Our fair value continues to suggest that the Neola share is cheap.
LÄS MER